Trial intelligence / Profile preview

Aliskiren + Amlodipine in Amlodipine-Refractory Hypertension

NCT00219076Phase 3Completed

Sponsor
Novartis
Start
Feb 2005
Primary completion
Oct 2005
Modality
Small Molecules
Countries
2
01

Overview

A Phase 3 trial of aliskiren in essential hypertension, sponsored by Novartis. Started Feb 2005; status: completed.

02

Drugs

aliskiren
03

Conditions

essential hypertension

Beyond the preview

Go deeper on NCT00219076.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00219076.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call